Skip to main content Accessibility help
×
×
Home

Assessment and treatment of individuals at high risk for psychosis

  • Christina Andreou (a1), Barbara Bailey (a2) and Stefan Borgwardt (a3)
Summary

Early detection and specialised early intervention for people at high risk for psychotic disorders have received growing attention in the past few decades, with the aim of delaying or preventing the outbreak of explicit psychotic symptoms and improving functional outcomes. This article summarises criteria for a diagnosis of high psychosis risk, the implications for such a diagnosis and recommendations for treatment.

LEARNING OBJECTIVES

After reading this article you will be able to:

  • recognise signs and symptoms indicating increased psychosis risk
  • understand uses and limitations of screening for high psychosis risk, and interpretation of results
  • recognise evidence-based treatment options for patients at clinical high risk for psychosis.

DECLARATION OF INTEREST

C.A. has received non-financial support from Sunovion and Lundbeck in the past 36 months.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Assessment and treatment of individuals at high risk for psychosis
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Assessment and treatment of individuals at high risk for psychosis
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Assessment and treatment of individuals at high risk for psychosis
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
Correspondence Professor Stefan Borgwardt, University Psychiatric Clinics Basel, Wilhelm Klein-Strasse 27, CH-4002 Basel, Switzerland. Email: stefan.borgwardt@upk.ch
References
Hide All
Addington, J, Addington, D, Abidi, S, et al. (2017) Canadian treatment guidelines for individuals at clinical high risk of psychosis. Canadian Journal of Psychiatry, 62: 656–66.
Amminger, GP, Schäfer, MR, Papageorgiou, K, et al. (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry, 67: 146–54.
Amminger, G, Schäfer, M, Schlögelhofer, M, et al. (2015) Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nature Communications, 6: 7934.
Bhattacharyya, S, Wilson, R, Appia-Kusi, E, et al. (2018) Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. JAMA Psychiatry, 75: 1107–17.
Boggs, DL, Surti, T, Gupta, A, et al. (2018) The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology, 235: 1923–32.
Cannon, TD, Yu, C, Addington, J, et al. (2016) An individualized risk calculator for research in prodromal psychosis. American Journal of Psychiatry, 173: 980–8.
Cornblatt, BA, Lencz, T, Smith, CW, et al. (2007) Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. Journal of Clinical Psychiatry, 68: 546–57.
Davies, C, Cipriani, A, Ioannidis, J, et al. (2018a) Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. World Psychiatry, 17: 196209.
Davies, C, Radua, J, Cipriani, A, et al. (2018b) Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: a network meta-analysis. Frontiers in Psychiatry, 9: 187.
Devoe, DJ, Farris, MS, Townes, P, et al. (2019) Attenuated psychotic symptom interventions in youth at risk of psychosis: a systematic review and meta-analysis. Early Intervention in Psychiatry, 13: 317.
Dong, C, Haschimoto, K (2015) Early intervention for psychosis with N-methyl-d-aspartate receptor modulators. Clinical Psychopharmacology and Neuroscience, 13: 328–9.
Emsley, R (2009) Early response to treatment predicts remission and recovery at 3 years in people with schizophrenia. Evidence-Based Mental Health, 12(2): 43.
Fusar-Poli, P, Borgwardt, S, Bechdolf, A, et al. (2013a) The psychosis high-risk state: a comprehensive state-of-the-art review. Archives of General Psychiatry, 70(1): 107–20.
Fusar-Poli, P, Bechdolf, A, Taylor, MJ, et al. (2013b) At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophrenia Bulletin, 39: 923–32.
Fusar-Poli, P, Cappucciati, M, Rutigliano, G, et al. (2015a) At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry, 14: 322–32.
Fusar-Poli, P, Frascarelli, M, Valmaggia, L, et al. (2015b) Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study. Psychological Medicine, 45: 1327–39.
Fusar-Poli, P, Cappucciati, M, Rutigliano, G, et al. (2016a) Towards a standard psychometric diagnostic interview for subjects at ultra high risk of psychosis: CAARMS versus SIPS. Psychiatry Journal, 2016: 111.
Fusar-Poli, P, Schultze-Lutter, F (2016b) Predicting the onset of psychosis in patients at clinical high risk: practical guide to probabilistic prognostic reasoning. Evidence-Based Mental Health, 19: 10–5.
Fusar-Poli, P, Díaz-Caneja, CM, Patel, R, et al. (2016c) Services for people at high risk improve outcomes in patients with first episode psychosis. Acta Psychiatrica Scandinavica, 133: 7685.
Fusar-Poli, P, Rutigliano, G, Stahl, D, et al. (2017a) Development and validation of a clinically based risk calculator for the transdiagnostic prediction of psychosis. JAMA Psychiatry, 74: 493500.
Fusar-Poli, P, McGorry, PD, Kane, JM (2017b) Improving outcomes of first-episode psychosis: an overview. World Psychiatry, 16: 251–65.
Gage, SH, Hickman, M, Zammit, S (2016) Association between cannabis and psychosis: epidemiologic evidence. Biological Psychiatry, 79: 549–56.
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390: 1211–59.
Häfner, H, Maurer, K, Löffler, W, et al. (1998) The ABC schizophrenia study: a preliminary overview of the results. Social Psychiatry and Psychiatric Epidemiology, 33(8): 380–6.
Iseger, TA, Bossong, MG (2015) A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research, 162: 153–61.
Jaaskelainen, E, Juola, P, Hirvonen, N, et al. (2013) A systematic review and meta-analysis of recovery in schizophrenia. Schizophrenia Bulletin, 39: 1296–306.
Khoury, JM, Neves, MdCLd, Roque, MAV, et al. (2017) Is there a role for cannabidiol in psychiatry? World Journal of Biological Psychiatry, Feb 20: doi: 10.1080/15622975.2017.1285049 [Epub ahead of print].
Klosterkötter, J, Ruhrmann, S, Schultze-Lutter, F, et al. (2005) The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry, 4: 161–7.
Klosterkötter, J, Schultze-Lutter, F, Bechdolf, A, et al. (2011) Prediction and prevention of schizophrenia: what has been achieved and where to go next? World Psychiatry, 10: 165–74.
Koutsouleris, N, Kambeitz-Ilankovic, L, Ruhrmann, S, et al. (2018) Prediction models of functional outcomes for individuals in the clinical high-risk state for psychosis or with recentonset depression: a multimodal, multisite machine learning analysis. JAMA Psychiatry, 75: 1156–72.
Leweke, FM, Piomelli, D, Pahlisch, F, et al. (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2: e94.
Lin, A, Wood, SJ, Nelson, B, et al. (2015) Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. American Journal of Psychiatry, 172: 249–58.
McGlashan, T, Walsch, B, Woods, S (2010) The Psychosis-Risk Syndrome. Handbook for Diagnosis and Follow-up. Oxford University Press.
McGorry, PD, Nelson, B, Markulev, C, et al. (2017) Effect of ω−3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry, 74: 1927.
McGuire, P, Robson, P, Cubala, WJ, et al. (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. American Journal of Psychiatry, 175: 225–31.
Mechelli, A, Lin, A, Wood, S, et al. (2017) Using clinical information to make individualized prognostic predictions in people at ultra high risk for psychosis. Schizophrenia Research, 184: 32–8.
Michel, C, Ruhrmann, S, Schimmelmann, BG, et al. (2018) Course of clinical high-risk states for psychosis beyond conversion. European Archives of Psychiatry and Clinical Neuroscience, 268: 3948.
Murray, RM, Quigley, H, Quattrone, D, et al. (2016) Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry, 15: 195204.
NAPLS (2018) NAPLS – The North American Prodrome Longitudinal Study. Yale University Campus Press (https://campuspress.yale.edu/napls). Accessed 17 July 2018.
National Institute for Health and Care Excellence (2014) Psychosis and Schizophrenia in Adults: Treatment and Management (NICE Clinical Guideline CG178). NICE.
Nelson, B, Yuen, HP, Lin, A, et al. (2016) Further examination of the reducing transition rate in ultra high risk for psychosis samples: the possible role of earlier intervention. Schizophrenia Research, 174: 43–9.
Nelson, B, Amminger, G, Yuen, H, et al. (2018) NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders – medium-term follow-up and clinical course. NPJ Schizophrenia, 4: 11.
Oliver, D, Davies, C, Crossland, G, et al. (2018) Can we reduce the duration of untreated psychosis? A systematic review and meta-analysis of controlled interventional studies. Schizophrenia Bulletin, 44: 1362–72.
Polari, A, Lavoie, S, Yuen, HP, et al. (2018) Clinical trajectories in the ultra-high risk for psychosis population. Schizophrenia Research, Feb 18: doi: 10.1016/j.schres.2018.01.022 [Epub ahead of print].
PRONIA (2018) PRONIA – Personalised Prognostic Tools for Early Psychosis Management. PRONIA (https://www.pronia.eu/the-project ). Accessed 17 July 2018.
Ruhrmann, S, Schultze-Lutter, F, Salokangas, RK, et al. (2010) Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Archives of General Psychiatry, 67: 241–51.
Schimmelmann, BG, Conus, P, Cotton, S, et al. (2007) Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophrenia Research, 95: 18.
Schimmelmann, BG, Walger, P, Schultze-Lutter, F (2013) The significance of at-risk symptoms for psychosis in children and adolescents. Canadian Journal of Psychiatry, 58: 3240.
Schmidt, SJ, Schultze-Lutter, F, Schimmelmann, BG, et al. (2015) EPA guidance on the early intervention in clinical high risk states of psychoses. European Psychiatry, 30: 388404.
Schmidt, A, Cappucciati, M, Radua, J, et al. (2017) Improving prognostic accuracy in subjects at clinical high risk for psychosis: systematic review of predictive models and meta-analytical sequential testing simulation. Schizophrenia bulletin, 43: 375–88.
Schultze-Lutter, F, Addington, J, Ruhrmann, S, et al. (2007) Schizophrenia Proneness Instrument, Adult Version. Giovanni Fioriti Editore.
Schultze-Lutter, F, Ruhrmann, S (2008) Früherkennung und Frühbehandlung von Psychosen. UNI-MED.
Schultze-Lutter, F, Koch, E (2010) Schizophrenia Proneness Instrument, Child & Youth Version (SPI-CY). Giovanni Fioriti Editore.
Schultze-Lutter, F, Michel, C, Schmidt, SJ, et al. (2015) EPA guidance on the early detection of clinical high risk states of psychoses. European Psychiatry, 30: 405–16.
Schultze-Lutter, F, Michel, C, Ruhrmann, S, et al. (2017) Prevalence and clinical relevance of interview-assessed psychosis-risk symptoms in the young adult community. Psychological Medicine, 48: 1167–78.
Simon, AE, Borgwardt, S, Riecher-Rössler, A, et al. (2013) Moving beyond transition outcomes: meta-analysis of remission rates in individuals at high clinical risk for psychosis. Psychiatry Research, 209: 266–72.
Studerus, E, Ramyead, A, Riecher-Rössler, A (2017) Prediction of transition to psychosis in patients with a clinical high risk for psychosis: a systematic review of methodology and reporting. Psychological Medicine, 47: 1163–78.
van der Gaag, M, Smit, F, Bechdolf, A, et al. (2013) Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophrenia Research, 149: 5662.
van Os, J, Guloksuz, S (2017) A critique of the “ultra-high risk” and “transition” paradigm. World Psychiatry, 16: 200–6.
Woods, SW, Kantrowitz, JT, Javitt, DC (2014) NMDAR-based treatments for patients at clinical high risk for psychosis. Biological Psychiatry, 1: 11S.
Yung, AR, Yung, AR, Pan Yuen, H, et al. (2005) Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Australian and New Zealand Journal of Psychiatry, 39: 964–71.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Advances
  • ISSN: 2056-4678
  • EISSN: 2056-4686
  • URL: /core/journals/bjpsych-advances
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Assessment and treatment of individuals at high risk for psychosis

  • Christina Andreou (a1), Barbara Bailey (a2) and Stefan Borgwardt (a3)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *